The Lancet’s Niall Boyce and Jonathan Pimm, and eBioMedicine’s Kalypso Karastergiou discuss an exciting new potential treatment for alcohol use disorder: semaglutide.

As new research is published in The Lancet, they go behind the headlines with lead author Professor Anders Fink-Jensen to ask what the study showed, and what its implications are for the future of addiction medicine.

Click here to read the full article: 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av, eller tillsammans med, Poddtoppen.